Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2021 | Combination treatment with CGRP mAbs and onabotulinumtoxinA for chronic migraine control

Andrew Blumenfeld, MD, The Neurology Center of Southern California, Carlsbad, CA, outlines a real-world retrospective study evaluating the combination of onabotulinumtoxinA and calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) for the control of chronic migraine patients. Patients included in this analysis had failed ≥ 2 oral preventative medications and had been treated with onabotulinumtoxinA for at least 6 months. The average headache frequency was 20 monthly headache days (MHDs) before initiation of onabotulinumtoxinA and 12 MHDs before adding CGRP mAbs. The results showed that combination treatment with onabotulinumtoxinA and CGRP mAbs significantly decreased monthly headache frequency compared to onabotulinumtoxinA monotherapy. This interview took place during the European Academy of Neurology 2021 congress.


Dr Blumenfeld reports the following disclosures:
Advisory Board: Allergan, Abbvie, Aeon, Alder, Amgen, Axsome, Biohaven, Impel, Lundbeck, Lilly, Novartis, Revance, Teva, Theranica, Zoscano
Speaker fees: Allergan, Abbvie, Amgen, Biohaven, Lundbeck, Lilly, Teva
Consultant: Allergan, Abbvie, Alder, Amgen, Biohaven, Lilly, Lundbeck, Novartis, Teva, Theranica
Grant support: Allergan, Amgen
Contributing author: Allergan, Abbvie, Amgen, Novartis, Teva, Lilly, Biohaven